1. Pink Sheet
  2. >>Geography
  3. >>International

PIC/S Resumes Assessment Of Countries Seeking To Join Inspection Scheme; Russian Application Frozen For Now

 
• By Neena Brizmohun

As it prepares to celebrate its 50th anniversary, the international Pharmaceutical Inspection Co-operation Scheme has set out its agenda for 2022, which includes revising its PIC/S GMP Guide and developing an inspection “aide memoire” for tissue and cellular therapy products.

Professional technologist using tablet in production plant checking productivity and quality.
The PIC/S aims to harmonize drug inspection procedures worldwide • Source: Shutterstock

The international Pharmaceutical Inspection Co-operation Scheme (PIC/S) says it is starting or resuming its assessments of applications from the latest countries whose competent authorities are seeking to join the initiative, with the exception of Russia.

Applications from Armenia, Azerbaijan, Bulgaria, China, Jordan and Saudi Arabia are tentatively scheduled to be assessed in Q2 or Q3 this year, according to the PIC/S, which had to put...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from International

ICH Targets RWE, Rare Diseases, Biosimilars, ATMPs In New Guideline Push

 
• By Vibha Sharma

The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.

Quotable: Top Experts On Policy Hot Topics

 
• By Anabel Costa-Ferreira

The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.

Global Pandemic Deal Adopted As 124 Countries Say Yes; US Sits Out

 
• By Neena Brizmohun

Now that the landmark Pandemic Agreement has finally been adopted, work will start on drafting a pathogen access and benefit sharing system that will be voluntary for use by drug companies.

Global Pharma Guidance Tracker - April 2025

 
• By Vibha Sharma and Anabel Costa-Ferreira

Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

More from Geography

UroGen’s Bladder Cancer Drug Draws Split Decision From US FDA Panel

 
• By Sue Sutter

The Oncologic Drugs Advisory Committee voted 5-4 that the overall benefit-risk of UGN-102 is not favorable in patients with recurrent low grade, intermediate-risk, non-muscle invasive bladder cancer and also divided on whether randomized trials should be required for future development programs.

US FDA Will Help States Apply To Import Cheaper Drugs From Canada

 
• By Cathy Kelly

The FDA is not currently signaling that stringent rules for the process will be relaxed, but the agency's change in approach is notable.

Global Pandemic Deal Adopted As 124 Countries Say Yes; US Sits Out

 
• By Neena Brizmohun

Now that the landmark Pandemic Agreement has finally been adopted, work will start on drafting a pathogen access and benefit sharing system that will be voluntary for use by drug companies.